Tuesday, February 19, 2013 10:42:32 AM
MENLO PARK, CA -- (Marketwire) -- 02/19/13 -- AntriaBio, Inc. (OTCQB: ANTB) is pleased to announce the appointment, on January 31, 2013 , of two new members to its management team: Nevan Elam , as AntriaBio's President and Chief Executive Officer and Sankaram Mantripragada , Ph.D., as AntriaBio's Chief Scientific Officer.
Nevan Elam has spent his entire career starting, managing and advising emerging growth companies in key areas of business including finance, marketing and clinical development. Prior to joining AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical Limited , a medical device company based in Europe . Prior to that, he directed the Pulmonary Business Unit of Nektar Therapeutics, which was sold to Novartis in 2008.
Mr. Elam also serves as a managing director of Konus Advisory Group, Inc. ("Konus"), a boutique healthcare consulting and investment firm that specializes in working with U.S. and European healthcare organizations on business opportunities in Asia , Latin America and the Middle East . Mr. Elam holds a J.D. from Harvard University and Bachelor's degree from Howard University .
Sankaram Mantripragada , Ph.D. brings to AntriaBio his strong understanding of the diabetes market and AntriaBio's unique platform technology. From June 2005 until October 2009 , Dr. Mantripragada served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP"). In January 2013 , AntriaBio purchased substantially all of the PRP assets including significant technology, formulation, manufacturing, and intellectual property assets, which together form the basis of AntriaBio's drug development portfolio.
"Dr. Mantripragada's history with PRP's technology and formulation assets and his deep experience in diabetes products and markets make him a clear choice to lead our product development efforts," said Steve Howe , Executive Chairman of AntriaBio. Mr. Howe served as Chairman and Chief Executive Officer of PRP from its formation in 1998 to 2010.
Dr. Mantripragada has been an advisor to companies specializing in diabetes, cell based therapies and cardiovascular diseases. He is listed as an inventor on more than eight patents.
Prior to joining PRP, Dr. Mantripragada served as Director of R&D at Guidant Corporation , now part of Abbott Vascular . Prior to that, he served as Director of R&D and VP of Scientific Development at SkyePharma. Prior to that, he was an Assistant Professor of Biochemistry at the University of Virginia School of Medicine . Dr. Mantripragada obtained his Ph.D. in Molecular Biophysics from the Indian Institute of Science and completed a postdoctoral research program at the Max Planck Institute for Biophysical Chemistry in Germany .
Recent RZLT News
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting • GlobeNewswire Inc. • 04/23/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 09:03:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2024 02:35:50 PM
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:47:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 04:55:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 10:00:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:20:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:10:54 PM
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update • GlobeNewswire Inc. • 02/13/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 10:15:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:36:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:06:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/25/2024 05:04:28 PM
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer • GlobeNewswire Inc. • 01/24/2024 01:00:00 PM
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/14/2023 09:01:36 PM
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”) • GlobeNewswire Inc. • 12/13/2023 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/30/2023 05:15:07 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 11/22/2023 10:16:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:35:47 PM
- Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day • GlobeNewswire Inc. • 11/17/2023 01:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM